Cargando…
Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity
Amphotericin B (AmB) is an amphiphilic drug commonly formulated in liposomes and administered intravenously to treat systemic fungal infections. Recent studies on the liposomal drug product have shed light on the AmB aggregation status in the bilayer, which heat treatment (curing) modifies. Although...
Autores principales: | Svirkin, Yuri, Lee, Jaeweon, Marx, Richard, Yoon, Seongkyu, Landrau, Nelson, Kaisar, Md Abul, Qin, Bin, Park, Jin H., Alam, Khondoker, Kozak, Darby, Wang, Yan, Xu, Xiaoming, Zheng, Jiwen, Rivnay, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shenyang Pharmaceutical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459057/ https://www.ncbi.nlm.nih.gov/pubmed/36105314 http://dx.doi.org/10.1016/j.ajps.2022.04.007 |
Ejemplares similares
-
Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022) -
Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022) -
Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022) -
Liposomal Amphotericin B Treatment and the Leishmaniases
por: Berman, Jonathan
Publicado: (2019) -
Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)